Skip to main content

Table 3 Baseline characteristics of patients having events compared to those without

From: Assessing cardiovascular risk in chronic kidney disease patients prior to kidney transplantation: clinical usefulness of a standardised cardiovascular assessment protocol

 

Event (n = 21)

No Event (n = 210)

 

Age

59.9 ± 11.1

52.8 ± 12.9

p = 0.015

Male

12 (57.1%)

122 (58.1%)

p = 0.933

High Cardiovascular Riska

20 (95.2%)

123 (58.6%)

p = 0.001

Body Mass Index (Kg/m2)

27.7 ± 4.7

27.8 ± 5.4

p = 0.948

Cholesterol (mmol/L)

3.67 ± 1.33

4.31 ± 1.19

p = 0.024

High Density Lipoprotein (mmol/L)

1.03 ± 0.34

1.25 ± 0.47

p = 0.054

Triglycerides (mmol/L)

1.49 ± 1.04

1.73 ± 0.96

p = 0.319

Parathyroid Hormone Level (pmol/L)

54.1 ± 56.3

40.2 ± 43.9

p = 0.182

C-Reactive Protein (mg/L)

14.6 ± 18.8

8.7 ± 14.2

p = 0.174

Haemoglobin (g/L)

106.8 ± 17.7

108.9 ± 17.6

p = 0.612

Ferritin (μg/L)

340.5 ± 474.7

276.8 ± 284.4

p = 0.365

Modality

p = 0.300

 Haemodialysis

8 (38.1%)

74 (35.2%)

 

 Peritoneal Dialysis

0 (0%)

7 (3.3%)

 Kidney Transplant

4 (19.0%)

17 (8.1%)

 No Renal Replacement Therapy

9 (42.9%)

112 (53.3%)

 Diabetes

12 (57.1%)

68 (32.4%)

p = 0.023

 Hypertension

20 (95.2%)

191 (91.0%)

p = 0.505

 Ischaemic Heart Disease

10 (47.6%)

21 (10.0%)

p = 0.000

 Ever smoked

9 (42.9%)

76 (36.2%)

p = 0.239

 Peripheral Vascular Disease

0 (0%)

4 (1.9%)

p = 0.523

 Cerebrovascular Accident/TIA

4 (19.0%)

12 (5.7%)

p = 0.022

 Congestive Cardiac Failure

1 (4.8%)

4 (1.9%)

p = 0.391

 ACEi/ARB

15 (71.4%)

84 (40.0%)

p = 0.006

 Antiplatelet

15 (71.4%)

44 (21.0%)

p = 0.000

 Beta-Blocker

11 (52.4%)

59 (28.1%)

p = 0.021

 Statin

15 (71.4%)

79 (37.6%)

p = 0.003

  1. Results are expressed as mean ± standard deviation or number and percentage (%) where indicated. Events were defined as the occurrence after referral for transplant evaluation of a non-fatal cardiovascular event (myocardial infarction, unstable angina, congestive heart failure, stroke, transient ischaemic attack and amputation) and sudden cardiac death or death from any cause
  2. aHigh Cardiovascular Risk according to our risk stratification protocol. ACEi Angiotensin Converting Enzyme Inhibitor, ARB Angiotensin II Receptor Blocker, Statin HMG CoA Reductase Inhibitor